Gene therapy restores vision in a canine model of childhood blindness
The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
The relationship between the neurosensory photoreceptors and the adjacent retinal pigment epithelium (RPE) controls not only normal retinal function, but also the pathogenesis of hereditary retinal degenerations. The molecular bases for both primary photoreceptor and RPE diseases that cause blindness have been identified. Gene therapy has been used successfully to slow degeneration in rodent models of primary photoreceptor diseases, but efficacy of gene therapy directed at photoreceptors and RPE in a large-animal model of human disease has not been reported. Here we study one of the most clinically severe retinal degenerations, Leber congenital amaurosis (LCA). LCA causes near total blindness in infancy and can result from mutations in RPE65 (LCA, type II; MIM 180069 and 204100). A naturally occurring animal model, the RPE65-/- dog, suffers from early and severe visual impairment similar to that seen in human LCA. We used a recombinant adeno-associated virus (AAV) carrying wild-type RPE65 (AAV-RPE65) to test the efficacy of gene therapy in this model. Our results indicate that visual function was restored in this large animal model of childhood blindness.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Since then, AAV-mediated gene delivery into the retina has been used in several proof-of-concept studies to target photoreceptors or the RPE in mice and larger models (such as dogs) [63,64,65].”
From The Ocular Gene Delivery Landscape (2021) · cites this paper as [64]
Citations
Cites
Rpe65 is necessary for production of 11-cis-vitamin A in the retinal visual cycle
Redmond., T. M., Yu, S., Lee, E., Bok, D., Hamasaki, D., Chen, N., Goletz, P., Ma, J.-X., Crouch, R. K., & Pfeifer, K. (1998) · Nature Genetics · doi:10.1038/3813 · Cited by 929
Identification of the gene responsible for Best macular dystrophy
Petrukhin, K., Koisti, M. J., Bakall, B., Li, W., Xie, G., Marknell, T., Sandgren, O., Forsman, K., Holmgren, G., Andreasson, S., et al. (1998) · Nature Genetics · doi:10.1038/915 · Cited by 689
Mutations in RPE65 cause autosomal recessive childhood–onset severe retinal dystrophy
Gu, S.-M., Thompson, D. A., Srikumari, C. R. S., Lorenz, B., Finckh, U., Nicoletti, A., Murthy, K. R., Rathmann, M., Kumaramanickavel, G., Denton, M. J., et al. (1997) · Nature Genetics · doi:10.1038/ng1097-194 · Cited by 663
Mutations in RPE65 cause Leber's congenital amaurosis
Marlhens, F., Bareil, C., Griffoin, J.-M., Zrenner, E., Amalric, P., Eliaou, C., Liu, S.-Y., Harris, E., Redmond, T. M., Arnaud, B., et al. (1997) · Nature Genetics · doi:10.1038/ng1097-139 · Cited by 606
Efficient photoreceptor-targeted gene expression in vivo by recombinant adeno-associated virus
Flannery, J. G., Zolotukhin, S., Vaquero, M. I., LaVail, M. M., Muzyczka, N., & Hauswirth, W. W. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.13.6916 · Cited by 407
Self-citationBiochemistry of visual pigment regeneration: the Friedenwald lecture.
Saari, J. C. (2000) · PubMed · Cited by 270
Simon, A., Hellman, U., Wernstedt, C., & Eriksson, U. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.3.1107 · Cited by 254
Van Hooser, J. P., Aleman, T. S., He, Y.-G., Cideciyan, A. V., Kuksa, V., Pittler, S. J., Stone, E. M., Jacobson, S. G., & Palczewski, K. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.150236297 · Cited by 252
Self-citationAguirre, G. K., Baldwin, V. J., Pearce‐Kelling, S., Narfström, K. L., Ray, K., & Acland, G. M. (1998) · PubMed · Cited by 244
Self-citationBennett, J., Maguire, A. M., Cideciyan, A. V., Schnell, M., Glover, E., Anand, V., Aleman, T. S., Chirmule, N., Gupta, A. R., Huang, Y., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.17.9920 · Cited by 242
Self-citation
Cited by
Items 401–500 of 1,000
Ocular drug delivery: advancements and innovations
Tian, B., Bilsbury, E., Doherty, S., Teebagy, S., Wood, E., Su, W., Gao, G., & Lin, H. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091931 · Cited by 50
Gene Therapy of Inherited Retinopathies: A Long and Successful Road from Viral Vectors to Patients
Colella, P., & Auricchio, A. (2012) · Human Gene Therapy · doi:10.1089/hum.2012.123 · Cited by 50
“In fact, a clinical trial (NCT01014052) that evaluates the efficacy of systemic administration of substitute chromophores to LCA2 patients has been recently initiated, and the preliminary efficacy results are encouraging (Cideciyan et al., 2012).”
BackgroundResultInfluentialLocal Overexpression of Nerve Growth Factor in Rat Corneal Transplants Improves Allograft Survival
Gong, N., Pleyer, U., Vogt, K., Anegón, I., Flügel, A., Volk, H., & Ritter, T. (2007) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.06-1084 · Cited by 52
Post-pegylated lipoplexes are promising vehicles for gene delivery in RPE cells
Peeters, L., Sanders, N. N., Jones, A. T., Demeester, J., & Smedt, S. C. D. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.05.033 · Cited by 50
Gene therapy for ocular angiogenesis
BAINBRIDGE, J. W. B., MISTRY, A. R., THRASHER, A. J., & ALI, R. R. (2003) · Clinical Science · doi:10.1042/cs20020314 · Cited by 50
Gene therapy for optic nerve disease
Martin, K. R. G., & Quigley, H. A. (2004) · Eye · doi:10.1038/sj.eye.6701579 · Cited by 55
Pseudotyped AAV vectors for constitutive and regulated gene expression in the eye
Auricchio, A. (2003) · Vision Research · doi:10.1016/s0042-6989(02)00676-4 · Cited by 57
Personalized therapeutic strategies for patients with retinitis pigmentosa
Zheng, A., Li, Y., & Tsang, S. H. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1006192 · Cited by 60
“Only recently in 2009 were the first transgenic dogs created expressing a red-fluorescent protein construct [56], and as such, many studies of eye disease in dog models, including RPE65 LCA and achromatopsia, have focused on naturally occurring mutations instead [31,57,58].”
BackgroundPromising and delivering gene therapies for vision loss
Carvalho, L. S., & Vandenberghe, L. H. (2015) · Vision Research · doi:10.1016/j.visres.2014.07.013 · Cited by 49
Animal Models for Target Diseases in Gene Therapy — using DNA and siRNA Delivery Strategies
Blagbrough, I. S., & Zara, C. (2008) · Pharmaceutical Research · doi:10.1007/s11095-008-9646-8 · Cited by 54
“So, visual function was restored in this animal model of childhood blindness with rAAV delivery of wild-type RPE65 (AAVRPE65) (101).”
BackgroundPathways and disease-causing alterations in visual chromophore production for vertebrate vision
Kiser, P. D., & Palczewski, K. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.rev120.014405 · Cited by 53
“Such technology was successfully extended to a large animal model of a human disease carrying an RPE65 mutation (150) (Fig.”
BackgroundPreservation of vision following cell-based therapies in a model of retinal degenerative disease
McGill, T. J., Lund, R. D., Douglas, R. M., Wang, S., Lü, B., & Prusky, G. T. (2004) · Vision Research · doi:10.1016/j.visres.2004.05.025 · Cited by 50
“Although numerous studies have slowed the progress of photoreceptor degeneration in animal models of retinal degenerative diseases (e.g. Acland et al., 2001; Ali et al., 2000; Li et al., 1998), very little attention has been paid to how photoreceptor rescue translates into rescue of…”
Hennig, A. K., Ogilvie, J. M., Ohlemiller, K. K., Timmers, A. M., Hauswirth, W. W., & Sands, M. S. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.03.018 · Cited by 49
Self-citationKoilkonda, R. D. (2010) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2010.135 · Cited by 48
Iris pigment epithelial cell transplantation for degenerative retinal diseases
Abe, T., YOSHIDA, M., YOSHIOKA, Y., Wakusawa, R., Tokita-Ishikawa, Y., Seto, H., Tamai, M., & Nishida, K. (2007) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2007.01.003 · Cited by 51
Simulation of thalamic prosthetic vision: reading accuracy, speed, and acuity in sighted humans
Vurro, M., Crowell, A. M., & Pezaris, J. S. (2014) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2014.00816 · Cited by 48
Gene Transfer to Ocular Stem Cells by Early Gestational Intraamniotic Injection of Lentiviral Vector
Endo, M., Zoltick, P. W., Chung, D. C., Bennett, J., Radu, A. P., Muvarak, N. E., & Flake, A. W. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300092 · Cited by 51
Self-citationAhn, J., Beharry, S., Molday, L. L., & Molday, R. S. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m304236200 · Cited by 48
AAV-mediated Gene Therapy Halts Retinal Degeneration in PDE6β-deficient Dogs
Pichard, V., Provost, N., Mendes-Madeira, A., Libeau, L., Hulin, P., Tshilenge, K.-T., Biget, M., Ameline, B., Deschamps, J.-Y., Weber, M., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2016.37 · Cited by 47
Genome engineering in ophthalmology: Application of CRISPR/Cas to the treatment of eye disease
Hung, S. S. C., McCaughey, T., Swann, O. G., Pébay, A., & Hewitt, A. W. (2016) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2016.05.001 · Cited by 54
Genetic defects in vitamin A metabolism of the retinal pigment epithelium
Thompson, D. A., & Gal, A. (2003) · Developments in Ophthalmology · doi:10.1159/000072044 · Cited by 47
Iron metabolism in the eye: A review
Goralska, M., Ferrell, J., Harned, J., Lall, M. M., Nagar, S., Fleisher, L. N., & McGahan, M. C. (2008) · Experimental Eye Research · doi:10.1016/j.exer.2008.10.026 · Cited by 56
“Briard dogs with mutations in RPE65 are blind, but blindness can be reversed by delivery of the RPE65 gene (Acland et al. 2001).”
BackgroundThe dog genome map and its use in mammalian comparative genomics.
Switonski, M., Szczerbal, I., & Nowacka‐Woszuk, J. (2004) · PubMed · Cited by 47
Advances in the molecular understanding of canine retinal diseases
Petersen‐Jones, S. M. (2005) · Journal of Small Animal Practice · doi:10.1111/j.1748-5827.2005.tb00333.x · Cited by 55
Ku, C. A., Chiodo, V. A., Boye, S. L., Goldberg, A. F. X., Li, T., Hauswirth, W. W., & Ramamurthy, V. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr391 · Cited by 46
Self-citationGene Therapy of Inherited Retinal Degenerations: Prospects and Challenges
Trapani, I., Banfi, S., Simonelli, F., Surace, E. M., & Auricchio, A. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.030 · Cited by 47
Goldstein, O., Mezey, J. G., Boyko, A. R., Gao, C., Wang, W., Bustamante, C. D., Anguish, L. J., Jordan, J. A., Pearce-Kelling, S. E., Aguirre, G. K., et al. (2010) · PubMed Central · Cited by 47
Self-citationNarfström, K. L., Bragadóttir, R., Redmond, T. M., Rakoczy, P. E., Veen, T. V., & Bruun, A. (2003) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-0067-4_54 · Cited by 50
Adamus, G., Sugden, B., Shiraga, S., Timmers, A. M., & Hauswirth, W. W. (2003) · Journal of Autoimmunity · doi:10.1016/s0896-8411(03)00092-1 · Cited by 50
Self-citationThe use of canine models of inherited retinal degeneration to test novel therapeutic approaches
Beltran, W. A. (2009) · Veterinary Ophthalmology · doi:10.1111/j.1463-5224.2009.00694.x · Cited by 55
Mutational Screening of LCA Genes Emphasizing RPE65 in South Indian Cohort of Patients
Verma, A., Vijayalakshmi, P., Shetty, S. B., Külm, M., & Sundaresan, P. (2013) · PLoS ONE · doi:10.1371/journal.pone.0073172 · Cited by 47
“For the management of LCA patients, the most promising aspect is the gene therapy success for RPE65 LCA cases, achieved in phase 2&1 clinical trials and previous animal model studies, which have paved the pathway to cure inherited blindness [11,12].”
BackgroundLe Meur, G. (2005) · Archives of Ophthalmology · doi:10.1001/archopht.123.4.500 · Cited by 46
“In dogs, 2 studies have reported the restoration of vision in a canine model of Leber congenital amaurosis.(24,25) Although restoration of vision was observed in some Briard dogs using AAV-2– mediated delivery of the canine RPE65 gene, rAAV serotypes that lead to exclusive transgene expression in RPE, such as rAAV-4,(…”
BackgroundPhillips, M. I. (2001) · Hypertension · doi:10.1161/hy09t1.092927 · Cited by 46
Li, W., Kong, F., Li, X., Dai, X., Liu, X., Zheng, Q., Wu, R., Zhou, X., Lü, F., Chang, B., et al. (2009) · PubMed Central · Cited by 54
Self-citationGene delivery to the retina: focus on non-viral approaches
Naik, R. J., Mukhopadhyay, A., & Ganguli, M. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2008.09.012 · Cited by 59
Thurtell, M. J., & Leigh, R. J. (2010) · Journal of Neuro-Ophthalmology · doi:10.1097/wno.0b013e3181e7518f · Cited by 51
Nour, M., Quiambao, A. B., Peterson, W. M., Al-Ubaidi, M. R., & Naash, M. I. (2003) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.03-0453 · Cited by 45
Treatment of experimental asthma by long-term gene therapy directed against IL-4 and IL-13
Zavorotinskaya, T., Tomkinson, A., & Murphy, J. E. (2003) · Molecular Therapy · doi:10.1016/s1525-0016(02)00050-3 · Cited by 47
Evaluation of 9-cis-Retinyl Acetate Therapy in Rpe65−/−Mice
Maeda, T., Maeda, A., Casadesus, G., Palczewski, K., & Margaron, P. (2009) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.09-3700 · Cited by 45
AAV-mediated gene transfer for retinal diseases
Allocca, M., Tessitore, A., Cotugno, G., & Auricchio, A. (2006) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.6.12.1279 · Cited by 44
“(2006) 6(12) testing and ERG measurements [49,52,76,77].”
BackgroundInfluentialSodi, A., Banfi, S., Testa, F., Della Corte, M., Passerini, I., Pelo, E., Rossi, S., Simonelli, F., & Italian IRD Working Group (2021) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-021-01868-4 · Cited by 44
Gene therapy for Leber congenital amaurosis: advances and future directions
Hufnagel, R. B., Ahmed, Z. M., Corrêa, Z. M., & Sisk, R. A. (2012) · Graefe's Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-012-2028-2 · Cited by 44
“Subretinal injections of AAV2 with CMV promoter and β-actin enhancer in 4month-old dogs resulted in improved ERGs, VEPs, pupillary response, and vision-dependent behaviors [37].”
BackgroundDissecting Neural Function Using Targeted Genome Engineering Technologies
Hsu, P. D., & Zhang, F. (2012) · ACS Chemical Neuroscience · doi:10.1021/cn300089k · Cited by 44
Ashtari, M., Nikonova, E. S., Marshall, K. A., Young, G. J., Aravand, P., Pan, W., Ying, G.-S., Willett, A. E., Mahmoudian, M., Maguire, A. M., et al. (2017) · Ophthalmology · doi:10.1016/j.ophtha.2017.01.029 · Cited by 44
Self-citationConflict of interest: the authors declare no conflict of interest.
Baygildin, S. S., Мусина, Л. А., & Khismatullina, Z. R. (2021) · Journal Biomed · doi:10.33647/2074-5982-17-1-70-81 · Cited by 45
Nonviral ocular gene therapy: assessment and future directions.
Conley, S. M., Cai, X., & Naash, M. I. (2008) · PubMed · Cited by 54
Adeno-associated viral vectors for retinal gene transfer
Surace, E. M., & Auricchio, A. (2003) · Progress in Retinal and Eye Research · doi:10.1016/s1350-9462(03)00052-1 · Cited by 47
Widespread expression of an exogenous gene in the eye after intravenous administration.
Zhu, C., Zhang, Y., & Pardridge, W. M. (2002) · PubMed · Cited by 49
Barriers for retinal gene therapy: separating fact from fiction.
Kumar-Singh, R. (2008) · Vision Research · doi:10.1016/j.visres.2008.05.005 · Cited by 43
“However, some disorders such as retinitis pigmentosa (RP), are much more common than LCA and are typically associated with degeneration of the rod photoreceptor cells due to mutations in genes expressed exclusively in those cells (Hartong, Berson, & Dryja, 2006).”
BackgroundInfluentialGenetic manipulation for inherited neurodegenerative diseases: myth or reality?
Yu-Wai-Man, P. (2016) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2015-308329 · Cited by 43
Greenwald, S. H., Charette, J. R., Staniszewska, M. M., Shi, L. Y., Brown, S. D. M., Stone, L. V., Liu, Q., Hicks, W. L., Collin, G. B., Bowl, M. R., et al. (2016) · American Journal Of Pathology · doi:10.1016/j.ajpath.2016.03.013 · Cited by 47
“Given that amaurosis is observed in homozygous Nmnat1 V9M mice, recovery of the pupillary light response could provide an additional noninvasive assessment of therapeutic ef fi cacy 78 ; this method was used in gene augmentation for RPE65 -LCA in dogs 79 and humans.”
MethodBarkBase: Epigenomic Annotation of Canine Genomes
Megquier, K., Genereux, D. P., Hekman, J. P., Swofford, R., Turner-Maier, J., Johnson, J., Alonso, J., Li, X., Morrill, K. M., Anguish, L. J., et al. (2019) · Genes · doi:10.3390/genes10060433 · Cited by 50
Translating CRISPR-Cas Therapeutics: Approaches and Challenges
Tay, L. S., Palmer, N. D., Panwala, R., Chew, W. L., & Mali, P. (2020) · The CRISPR Journal · doi:10.1089/crispr.2020.0025 · Cited by 48
“More importantly, the therapy demonstrated cortex recovery and response to visual stimulation despite prolonged visual deprivation in the RPE65-mutant dogs.(129,130) The results suggested safety of the AAV2 subretinal injection and some level of vision restoration when RPE65 was first introduced in LCA patients.”
Vražič, D., Jereb, M., Laali, K. K., & Stavber, S. (2012) · Molecules · doi:10.3390/molecules18010074 · Cited by 43
“Viral or nonviral vectors have their own usage in different conditions [23-28].”
BackgroundHo, T. T., Maguire, A. M., Aguirre, G. D., Surace, E. M., Anand, V., Zeng, Y., Salvetti, A., Hopwood, J. J., Haskins, M. E., & Bennett, J. (2002) · The Journal of Gene Medicine · doi:10.1002/jgm.302 · Cited by 43
“This is the second demonstration that AAV can be used effectively to treat disease originating in the RPE [16].”
BackgroundMethodSelf-citationNon-invasive gene transfer by iontophoresis for therapy of an inherited retinal degeneration
Souied, E. H., Reid, S. N. M., Piri, N., Lerner, L. E., Nusinowitz, S., & Farber, D. B. (2008) · Experimental Eye Research · doi:10.1016/j.exer.2008.04.009 · Cited by 46
“Gene therapy trials conducted in animal models of RP employed different types of viral vectors delivered by an intraocular injection into the subretinal space or vitreous cavity (Acland et al., 2001; Dejneka et al., 2003; Mashhour et al., 1994; Miyoshi et al., 1997; Takahashi et al., 1999).”
BackgroundPEG–PLA microparticles for encapsulation and delivery of Tat-EGFP to retinal cells
Rafat, M., Cléroux, C. A., Fong, W. G., Baker, A. N., Leonard, B. C., O’Connor, M. D., & Tsilfidis, C. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.01.031 · Cited by 47
“In addition, viral vectors can persist for years in vivo [9,10], and cannot be deactivated in cases presenting long-term side effects.”
BackgroundEfficiency of lentiviral transduction during development in normal and rd mice.
Pang, J., Cheng, M., Haire, S. E., Barker, E., Planelles, V., & Blanks, J. C. (2006) · PubMed · Cited by 47
Traverso, V., Kinkl, N., Grimm, L. L., Sahel, J., & Hicks, D. (2003) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.03-0460 · Cited by 52
Gene Transfer to Rabbit Retina with Electron Avalanche Transfection
Chalberg, T. W., Vankov, A., Molnar, F. E., Butterwick, A. F., Huie, P., Calos, M. P., & Palanker, D. V. (2006) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.06-0092 · Cited by 42
Elevation of intraocular pressure in rodents using viral vectors targeting the trabecular meshwork
Pang, I., Millar, J. C., & Clark, A. F. (2015) · Experimental Eye Research · doi:10.1016/j.exer.2015.04.003 · Cited by 42
“Recombinant AAV vectors do not possess viral open reading frames and are thus only very mildly immunogenic, although a humoral response can result from exposure to the AAV capsid (Bennett et al., 2000; Acland et al., 2001; Acland et al., 2005).”
BackgroundEndo, M., Zoltick, P. W., Chung, D. C., Bennett, J., & Flake, A. W. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.08.111 · Cited by 42
Self-citationStem cell-based delivery of brain-derived neurotrophic factor gene in the rat retina
Park, H.-Y. L., Kim, J., Kim, H. S., & Park, C. K. (2012) · Brain Research · doi:10.1016/j.brainres.2012.06.006 · Cited by 44
Penha, F. M., Rodrigues, E. B., Maia, M., Dib, E., Costa, E. D. P. F., Furlani, B. A., Filho, M. N. M., Dreyfuss, J. L., Bottós, J. M., & Farah, M. E. (2010) · Ophthalmic Research · doi:10.1159/000312817 · Cited by 43
“Dogs The dog is an important large animal for human retinal disease. Canine models have been reported in the literature as a good option in the investigation of genetic retinal degenerative diseases, diabetic retinopathy and ROP. The most relevant application of a canine model has been in Leber congenital amaurosis, o…”
BackgroundPolymeric Vectors for Ocular Gene Delivery
Tamboli, V., Mishra, G. P., & Mitra, A. K. (2011) · Therapeutic Delivery · doi:10.4155/tde.11.20 · Cited by 45
Kuksa, V., Bartl, F., Maeda, T., Jang, G.-F., Ritter, E., Heck, M., Van Hooser, J. P., Liang, Y., Filipek, S., Gelb, M. H., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m206014200 · Cited by 42
An ABCA4 loss-of-function mutation causes a canine form of Stargardt disease
Mäkeläinen, S., Gòdia, M., Hellsand, M., Viluma, A., Hahn, D., Makdoumi, K., Zeiss, C. J., Mellersh, C., Ricketts, S. L., Narfström, K., et al. (2019) · PLOS Genetics · doi:10.1371/journal.pgen.1007873 · Cited by 41
QLT091001, a 9-cis-Retinal Analog, Is Well-Tolerated by Retinas of Mice with Impaired Visual Cycles
Maeda, T., Dong, Z., Jin, H., Sawada, O., Gao, S., Utkhede, D., Monk, W., Palczewska, G., & Palczewski, K. (2013) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.12-11152 · Cited by 41
“Whether such ester accumulation is pathological remains unclear, but it must be considered when pharmacological rescue of vision is employed in animal models and humans with defective 11-cis-retinal renewal.(15,35,36) Pharmacological retinoid replacement therapy for 11-cisretinal deficiency offers great promise for tr…”
BackgroundHasegawa, T., Ikeda, H. O., Iwai, S., Muraoka, Y., Tsuruyama, T., Okamoto‐Furuta, K., Kohda, H., Kakizuka, A., & Yoshimura, N. (2018) · Heliyon · doi:10.1016/j.heliyon.2018.e00544 · Cited by 42
“No established therapies are available, although potential therapies, including regenerative medicine (Ng et al., 2014), gene therapy (Acland et al., 2001), and neurotropic factor therapy (Sieving et al., 2006), are currently being pursued.”
BackgroundNystagmus and saccadic intrusions
Thurtell, M. J., & Leigh, R. J. (2011) · Handbook of clinical neurology · doi:10.1016/b978-0-444-52903-9.00019-4 · Cited by 48
Borrás, T., Buie, L. K., Spiga, M., & Carabaña, J. (2014) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2014.4747 · Cited by 41
Gene Therapy Progress and Prospects: Stem cell plasticity
Kashofer, K., & Bonnet, D. A. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302571 · Cited by 43
Ishiba, Y., Higashide, T., Mori, N., Kobayashi, A., Kubota, S., McLaren, M. J., Satoh, H., Wong, F., & Inana, G. (2006) · Experimental Eye Research · doi:10.1016/j.exer.2006.10.016 · Cited by 45
“Along this line, very encouraging results were obtained from gene therapy of a dog model of Leber congenital amaurosis (Acland et al., 2001).”
ResultGene Therapy and Animal Models for Retinal Disease
Dejneka, N. S., Rex, T. S., & Bennett, J. (2003) · KARGER eBooks · doi:10.1159/000072047 · Cited by 47
Self-citationGene Therapy of ABCA4-Associated Diseases
Auricchio, A., Trapani, I., & Allikmets, R. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a017301 · Cited by 41
“Most well known have been reports that a recombinant adeno-associated virus (rAAV) carrying wild-type Rpe65 (rAAV-Rpe65) improved visual function in the Briard dog model of childhood blindness (Acland et al. 2001; Narfstrom et al. 2003; Le Meur et al. 2007).”
BackgroundAdeno-Associated Virus (AAV) - Based Gene Therapies for Retinal Diseases: Where are We?
Ail, D., Malki, H., Zin, E. A., & Dalkara, D. (2023) · The Application of Clinical Genetics · doi:10.2147/tacg.s383453 · Cited by 40
“The proof-of-concept for vision restoration was provided in a canine model.(14) This led to clinical trials involving LCA2 patients who received SR injections of RPE65 packaged in AAV2 via SR delivery.”
BackgroundEstablishment and evolution of the A ustralian I nherited R etinal D isease R egister and DNA B ank
Roach, J. N. D., McLaren, T. L., Paterson, R. L., O'Brien, E. C., Hoffmann, L., Mackey, D. A., Hewitt, A. W., & Lamey, T. M. (2012) · Clinical and Experimental Ophthalmology · doi:10.1111/ceo.12020 · Cited by 42
Han, Z., Conley, S. M., & Naash, M. I. (2011) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.10-6916 · Cited by 40
“Reviews Investigative Ophthalmology & Visual Science, May 2011, Vol. 52, No. 6 Copyright 2011 The Association for Research in Vision and Ophthalmology, Inc. 3051 mutation in RPE65.”
BackgroundMurakami, Y., Ikeda, Y., Yonemitsu, Y., Miyazaki, M., Inoue, M., Hasegawa, M., Sueishi, K., & Ishibashi, T. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.102 · Cited by 40
“…and lentiviral vectors are likely to be useful for patients with chronic progressive retinal diseases, as these vectors can achieve gene transfer in nondividing cells and yield long-term transgene expression (Miyoshi et al. , 1997; Acland et al. , 2001; Lai et al. , 2002; Ikeda et al. , 2003).”
Contemporary Animal Models For Human Gene Therapy Applications
Gopinath, C., Nathar, T. J., Ghosh, A., Hickstein, D. D., & Nelson, E. J. R. (2015) · Current Gene Therapy · doi:10.2174/1566523215666150929110424 · Cited by 49
Yzer, S., Fishman, G. A., Racine, J., Al-Zuhaibi, S. S., Chakor, H., Dorfman, A. L., Szlyk, J. P., Lachapelle, P., van den Born, L. I., Allikmets, R. L., et al. (2006) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.05-1637 · Cited by 39
Advances in AAV-mediated gene transfer for the treatment of inherited disorders
Hildinger, M., & Auricchio, A. (2004) · European Journal of Human Genetics · doi:10.1038/sj.ejhg.5201153 · Cited by 46
Sustained Transduction of Ocular Cells with a Bovine Immunodeficiency Viral Vector
Takahashi, K., Luo, T., Saishin, Y., Saishin, Y., Sung, J., Hackett, S. F., Brazzell, R. K., Kaleko, M., & Campochiaro, P. A. (2002) · Human Gene Therapy · doi:10.1089/104303402760128531 · Cited by 44
Hauswirth, W. W., Alemán, T. S., Kaushal, S., Cideciyan, A. V., Schwartz, S., Wang, L., Conlon, T. J., Boye, S. L., Flotte, T. R., Byrne, B. J., et al. (2008) · Human Gene Therapy · doi:10.1089/hgt.2008.107 · Cited by 47
Self-citationNystagmus and Saccadic Intrusions and Oscillations
Dell’Osso, L. F. (2014) · Encyclopedia of the Neurological Sciences · doi:10.1016/b978-0-12-385157-4.00144-5 · Cited by 40
Focused Update on AAV-Based Gene Therapy Clinical Trials for Inherited Retinal Degeneration
Fuller-Carter, P. I., Basiri, H., Harvey, A. R., & Carvalho, L. S. (2020) · BioDrugs · doi:10.1007/s40259-020-00453-8 · Cited by 41
“Whilst many forms exhibit complex aetiology, IRDs are largely monogenic and typically progressive, exhibiting a wide range of presenting age and variability in visual disturbance.”
BackgroundInfluentialOverview of Adeno-Associated Viral Vectors
Daly, T. M. (2004) · Humana Press eBooks · doi:10.1385/1-59259-650-9:157 · Cited by 48
Miyadera, K., Kato, K., Aguirre‐Hernández, J., Tokuriki, T., Morimoto, K., Busse, C., Barnett, K. C., Holmes, N. G., Ogawa, H., Sasaki, N., et al. (2009) · PubMed Central · Cited by 38
Bone marrow–derived stem cells preserve cone vision in retinitis pigmentosa
Smith, L. E. H. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200422930 · Cited by 40
Leber Congenital Amaurosis: From Darkness to Spotlight
Kaplan, J. (2008) · Ophthalmic Genetics · doi:10.1080/13816810802232768 · Cited by 43
Molecular Testing for Hereditary Retinal Disease as Part of Clinical Care
Downs, K., Zacks, D. N., Caruso, R., Karoukis, A. J., Branham, K., Yashar, B. M., Haimann, M. H., Trzupek, K., Meltzer, M., Blain, D., et al. (2007) · Archives of Ophthalmology · doi:10.1001/archopht.125.2.252 · Cited by 39
Comparison of gene expression after intraperitoneal delivery of AAV2 or AAV5 in utero
Lipshutz, G. S., Titre, D., Brindle, M. E., Bisconte, A. R., Contag, C. H., & Gaensler, K. M. L. (2003) · Molecular Therapy · doi:10.1016/s1525-0016(03)00132-1 · Cited by 37
Hashida, N., & Nishida, K. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114870 · Cited by 38
Borrás, T., Buie, L. K., & Spiga, M. (2016) · Gene Therapy · doi:10.1038/gt.2016.14 · Cited by 38
Sumaroka, A., Garafalo, A. V., Semenov, E. P., Sheplock, R., Krishnan, A. K., Roman, A. J., Jacobson, S. G., & Cideciyan, A. V. (2019) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.19-27156 · Cited by 38
Self-citationBeltran, W. A., Wen, R., Acland, G. M., & Aguirre, G. K. (2007) · Experimental Eye Research · doi:10.1016/j.exer.2006.12.019 · Cited by 39
“A promising therapeutic approach, for which proof of principle has been demonstrated in various animal models, is the use of corrective gene therapy (Acland et al., 2001; Pang et al., 2006).”
BackgroundSelf-citationMentzer, A. E., Eifler, D. M., Montiani‐Ferreira, F., Tuntivanich, N., Forcier, J. Q., & Petersen‐Jones, S. M. (2005) · Documenta Ophthalmologica · doi:10.1007/s10633-005-4517-7 · Cited by 48
“naturally occurring retinal dystrophies is becoming more established as a model for human disease and a species for investigation of therapeutic modalities [5–8].”
Photoreceptor-targeted gene delivery using intravitreally administered AAV vectors in dogs
Boyd, R. F., Sledge, D. G., Boye, S. L., Boye, S. E., Hauswirth, W. W., Komáromy, A. M., Petersen-Jones, S. M., & Bartoe, J. T. (2016) · Gene Therapy · doi:10.1038/gt.2015.96 · Cited by 38
Self-citationSmelling the roses and seeing the light: gene therapy for ciliopathies
McIntyre, J. C., Williams, C. L., & Martens, J. R. (2013) · Trends in biotechnology · doi:10.1016/j.tibtech.2013.03.005 · Cited by 44
“These reports build upon early successes demonstrated in clinical trials of gene therapy treatment of non-ciliary retinal diseases [18-20] and answer several fundamental questions concerning the primary challenges inherent in restoring function to a genetically and functionally diverse organelle.”
ResultShamir, M. H., Ofri, R., Bor, A., Brenner, O. J., Reicher, S., Obolensky, A., Averbukh, E., Banin, E., & Gootwine, E. (2009) · The Veterinary Journal · doi:10.1016/j.tvjl.2009.05.029 · Cited by 40
Metadata
- Authors
- Acland, G. M., Aguirre, G. D., Ray, J., Zhang, Q., Aleman, T. S., Cideciyan, A. V., Pearce-Kelling, S. E., Anand, V., Zeng, Y., Maguire, A. M., Jacobson, S. G., Hauswirth, W. W., & Bennett, J.
- Affiliations
- Cornell University (US)
- University of Pennsylvania (US)
- University of Florida (US)
- Corresponding author
- Bennett, Jean
- ORCID
- Venue
- Nature Genetics
- Published
- 2001-05
- Volume
- 28
- Issue
- 1
- Pages
- 92-95
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W2141354154
- Cited by
- 1,202
- References
- 21
- Citations by year
- 2026: 29 · 2025: 26 · 2024: 19 · 2023: 24 · 2022: 26 · 2021: 38 · 2020: 35 · 2019: 36 · 2018: 39 · 2017: 41 · 2016: 33 · 2015: 40 · 2014: 56 · 2013: 48 · 2012: 64
- FWCI
- 22.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r01ey011142-05)
- National Eye Institute (EY10820, EY 06855, R01EY010820, EY 11142, R01EY013132, R01EY011123, EY-11123, EY 13132)
- National Institute of Neurological Disorders and Stroke (NS36202)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Keywords
- gene therapy, Leber congenital amaurosis, RPE65, retinal pigment epithelium, photoreceptors, recombinant adeno-associated virus, childhood blindness, vision restoration, inherited retinal degeneration, large animal model
- MeSH terms
- Retinoid Isomerohydrolase, Dependovirus, Animals, Blindness, Carrier Proteins, Disease Models, Animal, Dog Diseases, Dogs, Eye Proteins, Proteins, Genetic Therapy, Optic Atrophies, Hereditary, cis-trans-Isomerases, Animals, Genetically Modified
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.